Pacific Biosciences of California Inc. (NASDAQ:PACB) concluded the trading at $5.41 on Thursday, September 22 with a fall of -5.42% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $5.72 and 5Y monthly beta was reading 1.51 with its price kept floating in the range of $5.34 and $5.69 on the day. Considering stock’s 52-week price range provides that PACB hit a high price of $31.10 and saw its price falling to a low level of $3.85 during that period. Over a period of past 1-month, stock came subtracting -9.98% in its value.
With its current market valuation of $1.34 billion, Pacific Biosciences of California Inc. is set to declare its quarterly results on Apr 27, 2022 – May 02, 2022. Analysts are in estimates of -$0.32 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.36 for 2022 with estimates of that growing to -$1.27 in next year. These estimates are suggesting current year growth of -54.50% for EPS and 6.60% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $35.7 million. They suggested that in the process company could generate revenue of as low as $35 million which could climb up to $37.5 million to hit a high. The average estimate is representing an increase of 16.60% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $162.42 million in 2022, which will be 24.40% more from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review PACB stock’s current outlook then short term indicators are assigning it an average of Hold, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Sell for it.
Digging deeper we become aware of the PEG ratio of the PACB stock which is currently positioned at 0. It further provides that stock’s current price level is -11.03% away from its 20-day simple moving average and is -7.70% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 42.92 while volatility remained at 8.94% over the past week which changes to 10.39% when measuring it over the past month. Beta is valued at 1.30, while measure of average true range or ATR is currently at 0.66.
In comparing Pacific Biosciences of California Inc. (PACB)’s stock with other industry players reveals that stock’s current price change of -5.42% and that of -80.17% over the past 12 months is in competing position with that of Thermo Fisher Scientific Inc. (TMO) which saw its stock price fall by -1.03% in the last trading and went through a decrease of -14.23% in past 12-month trading. Industry’s another major player Standard BioTools Inc. (LAB) has fall -6.15% down in previous session, but over the past year has faced a fall of -81.54%, while Illumina Inc. (ILMN) was also down -2.36% however its price remained floating in the red at -55.48% over the same period. Pacific Biosciences of California Inc. has a P/E ratio of 0 against that of Thermo Fisher Scientific Inc.’s 27.68. On the other hand, the S&P 500 Index was down -0.84% in the last trading session while the Dow Jones Industrial closed the session lower at -0.35%.
Having a second look at Pacific Biosciences of California Inc. (NASDAQ:PACB) provides that stock’s average daily trading volume for 3 months was 7.94 million, while it jumped to 6.56 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 224.50 million.
The percentage of outstanding shares held by the insiders is 0.50% while it is 97.50% for the institutional holders. The figures also indicate that as of Jul 14, 2022, number of stock’s short shares was 36.03 million which implies a short ratio of 5.82. This shows down a 16.06% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short improved as it was 38.01 million in the previous month. Subtraction of -73.56% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.